Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 94,376 |
|
|||||
| News | - | ||||||
| Day High | 1.45 | Low High |
|||||
| Day Low | 1.35 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Inhibikase Therapeutics Inc | IKT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.12 | -8.16% | 1.35 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.43 | 1.35 | 1.45 | 1.35 | 1.47 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 535 | 94,376 | US$ 1.38 | US$ 129,944 | - | 0.79 - 4.3512 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:28:47 | 20 | US$ 1.37 | USD |
Inhibikase Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 8.34M | 6.17M | - | 261k | -19.03M | -3.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Inhibikase Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IKT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.63 | 1.90 | 1.35 | 1.69 | 56,064 | -0.28 | -17.18% |
| 1 Month | 2.13 | 2.30 | 1.29 | 1.75 | 57,485 | -0.78 | -36.62% |
| 3 Months | 2.70 | 2.9799 | 1.29 | 2.30 | 90,360 | -1.35 | -50.00% |
| 6 Months | 0.8917 | 3.82 | 0.7981 | 1.99 | 120,882 | 0.4583 | 51.40% |
| 1 Year | 3.252 | 4.3512 | 0.79 | 1.81 | 136,136 | -1.90 | -58.49% |
| 3 Years | 31.56 | 38.46 | 0.79 | 8.72 | 244,003 | -30.21 | -95.72% |
| 5 Years | 64.02 | 70.80 | 0.79 | 11.29 | 233,538 | -62.67 | -97.89% |
Inhibikase Therapeutics Description
| Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. |
